Derek J. Taylor
YOU?
Author Swipe
View article: Multivalent Nanobodies for Potent and Broad Neutralization of <i>Staphylococcus aureus</i> Toxins
Multivalent Nanobodies for Potent and Broad Neutralization of <i>Staphylococcus aureus</i> Toxins Open
Staphylococcus aureus is a leading cause of lethal bacteremia and pneumonia, which are driven by potent virulence factors such as T-cell superantigens and alpha hemolysin. S. aureus has among the highest rates of antibiotic resistance, yet…
View article: Pharmacologic activators of immunoproteasomes unmask actionable public and private neoantigens in multiple myeloma patients
Pharmacologic activators of immunoproteasomes unmask actionable public and private neoantigens in multiple myeloma patients Open
Immunotherapy has emerged as a powerful tool for myeloma-directed cytotoxicity with the unique potential to induce immune memory and reduce the risk of relapse. However, evasion of immune destruction is a cancer hallmark that thwarts the e…
View article: Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma
Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma Open
Introduction. Multiple myeloma (MM) is the second most common hematological malignancy. The emergence of novel agents has significantly extended patient survival, however, those with certain cytogenetic and clinical features are at risk of…
View article: A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer
A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer Open
The effectiveness of RAS/MAPK inhibitors in treating metastatic KRAS-mutant non-small cell lung cancer (NSCLC) is often hindered by the development of resistance driven by disrupted negative feedback mechanisms led by phosphatases like PP2…
View article: 15-PGDH inhibition enhances hematopoietic regeneration during aging
15-PGDH inhibition enhances hematopoietic regeneration during aging Open
Hematopoietic aging is characterized by diminished stem cell regenerative capacity and an increased risk of hematologic dysfunction. We previously identified that the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15…
View article: Cryo-EM structures reveal the PP2A–B55α and Eya3 interaction that can be disrupted by a peptide inhibitor
Cryo-EM structures reveal the PP2A–B55α and Eya3 interaction that can be disrupted by a peptide inhibitor Open
We have previously shown that Eya3 recruits PP2A-B55α to dephosphorylate pT58 on Myc, increasing Myc stability and enhancing primary tumor growth of triple-negative breast cancer (TNBC). However, the molecular details of how Eya3 recruits …
View article: 15-PGDH inhibition promotes hematopoietic recovery and enhances HSC function during aging
15-PGDH inhibition promotes hematopoietic recovery and enhances HSC function during aging Open
Hematopoietic aging is characterized by diminished stem cell regenerative capacity and an increased risk of hematologic dysfunction. We previously identified that the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15…
View article: Cryo-EM structures reveal the PP2A-B55α and Eya3 interaction that can be disrupted by a peptide inhibitor
Cryo-EM structures reveal the PP2A-B55α and Eya3 interaction that can be disrupted by a peptide inhibitor Open
We have previously shown that Eya3 recruits PP2A-B55α to dephosphorylate pT58 on Myc, increasing Myc stability and enhancing primary tumor growth of triple-negative breast cancer (TNBC). However, the molecular details of how Eya3 recruits …
View article: Supp Figure 6 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 6 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 6
View article: Supp Figure 4 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 4 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 4
View article: B56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
B56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Vector map for the B56-alpha overexpression (OE) plasmid
View article: Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 12
View article: Supp Figure 1 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 1 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 1
View article: Supp Figure 7 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 7 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 7
View article: Supp Figure 10 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 10 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 10
View article: Supp Figure 8 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 8 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 8
View article: TCGA Patient IDs from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
TCGA Patient IDs from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Patient IDs used for all TCGA analysis used in this manuscript
View article: Supp Figure 3 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 3 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 3
View article: Raw PCA Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Raw PCA Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Raw data of the PCA analysis from the Broad Institute Cell Line Encyclopedia
View article: Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 11
View article: Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Data from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) tumors are uniquely aggressive, suggesting that the primary tumor is intrinsically equipped to disseminate and metastasize. Previous work identified mutational hotspots within…
View article: Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 5
View article: Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 9
View article: Supplementary Figure Legends from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supplementary Figure Legends from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supplementary Figure Legends
View article: Supp Figure 2 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 2 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Supp Figure 2
View article: EGFP OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
EGFP OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Vector map for the EGFP overexpression (OE) plasmid
View article: IDEXX Cell Line Verification from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
IDEXX Cell Line Verification from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
Verification of cell lines employed in this manuscript.
View article: Key Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Key Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer Open
table of key resources and reagents used in this manuscript.